PFE analyst scorecard · Pfizer
30 rating actions on PFE in the last 12 months. Of 32 price targets that resolved, 16 were reached while they stood, 15 were replaced by the same firm first, and 1 fell short at their deadline. Ratings: 33% Buy-type, 57% Hold-type, 10% Sell-type. Consensus target $29, 2% below the last close.
Checked through 2026-10-29 · last close $29.80 (2026-10-29). Rebuilt every morning.
What the Holds say: 17 Hold-type ratings on PFE in the last 12 months carried a median target +6% from the price on the day; 18% sat below it.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Guggenheim | Buy | 2026-08-07 | $31 | 0 | 5 | 5 | 0 of 1 |
| Cantor Fitzgerald | Neutral | 2026-10-08 | $28 | 2 | 0 | 2 | — |
| JPMorgan | Neutral | 2026-10-09 | $30 | 2 | 0 | 2 | — |
| BMO Capital | Outperform | 2026-07-13 | $30 | 1 | 0 | 1 | — |
| Argus Research | Buy | 2026-03-02 | $35 | — | — | 0 | — |
| Freedom Broker | Buy | 2026-02-09 | $33 | — | — | 0 | — |
| RBC Capital | Sector Perform | 2026-06-10 | $25 | 2 | 0 | 2 | — |
| HSBC | Hold | 2026-09-10 | $30 | 2 | 1 | 3 | — |
| Bank of America | Neutral | 2026-07-10 | $26 | 2 | 2 | 4 | — |
| Morgan Stanley | Equal-Weight | 2026-04-10 | $28 | 1 | 4 | 5 | — |
| Scotiabank | Sector Outperform | 2026-10-06 | $33 | — | — | 0 | — |
| Citigroup | Neutral | 2026-04-29 | $27 | 1 | 1 | 2 | — |
| CICC | Outperform | 2026-04-16 | $33 | — | — | 0 | — |
| UBS | Neutral | 2026-04-13 | $27 | 1 | 2 | 3 | — |
| Barclays | Underweight | 2026-02-20 | $25 | 1 | 0 | 1 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor PFE carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | JPMorgan | Neutral | maintained | $28.28 | $30 | reached 2026-10-20 | +1.8% |
| 2026-10-08 | Cantor Fitzgerald | Neutral | maintained | $27.82 | $28 | within 5% of price when set | +0.1% |
| 2026-10-06 | Scotiabank | Sector Outperform | maintained | $27.50 | $33 | running to 2027-10-06 | -3.3% |
| 2026-09-10 | HSBC | Hold | maintained | $27.65 | $30 | reached 2026-10-20 | +3.9% |
| 2026-08-07 | Guggenheim | Buy | maintained | $26.76 | $31 | running to 2027-08-07 | +11.3% |
| 2026-07-13 | BMO Capital | Outperform | maintained | $24.48 | $30 | reached 2026-10-20 | -6.6% |
| 2026-07-13 | Guggenheim | Buy | maintained | $24.48 | $35 | replaced 2026-08-07, new $31 | -6.6% |
| 2026-07-10 | Bank of America | Neutral | maintained | $24.17 | $26 | reached 2026-08-06 | -5.6% |
| 2026-07-08 | JPMorgan | Neutral | maintained | $24.05 | $28 | reached 2026-08-19 | -6.1% |
| 2026-07-06 | Cantor Fitzgerald | Neutral | reiterated | $23.72 | $27 | reached 2026-08-10 | -8.9% |
| 2026-07-06 | HSBC | Buy → Hold | downgrade | $23.72 | $28 | reached 2026-08-19 | -8.9% |
| 2026-06-10 | RBC Capital | Underperform → Sector Perform | upgrade | $25.60 | $25 | within 5% of price when set | -0.8% |
| 2026-04-29 | Citigroup | Neutral | maintained | $26.26 | $27 | within 5% of price when set | -5.4% |
| 2026-04-20 | RBC Capital | Underperform | reiterated | $27.52 | $25 | reached 2026-06-23 | +2.0% |
| 2026-04-16 | CICC | Outperform | initiated | $27.22 | $33 | running to 2027-04-16 | -0.8% |
| 2026-04-13 | UBS | Neutral | maintained | $27.34 | $27 | within 5% of price when set | +2.9% |
| 2026-04-10 | Morgan Stanley | Equal-Weight | maintained | $26.92 | $28 | within 5% of price when set | -1.4% |
| 2026-04-09 | Bank of America | Neutral | maintained | $27.22 | $26 | within 5% of price when set | +0.2% |
| 2026-03-24 | Guggenheim | Buy | maintained | $26.96 | $36 | replaced 2026-07-13, new $35 | +1.2% |
| 2026-03-17 | HSBC | Buy | maintained | $27.45 | $32 | replaced 2026-07-06, new $28 | -0.5% |
| 2026-03-02 | Argus Research | Hold → Buy | upgrade | $27.26 | $35 | running to 2027-03-02 | +3.1% |
| 2026-02-25 | RBC Capital | Underperform | initiated | $27.09 | $25 | reached 2026-06-23 | +4.7% |
| 2026-02-20 | Barclays | Underweight | initiated | $26.65 | $25 | reached 2026-06-23 | +2.9% |
| 2026-02-09 | Freedom Broker | Buy | maintained | $27.05 | $33 | running to 2027-02-09 | +6.2% |
| 2026-02-04 | Cantor Fitzgerald | Neutral | reiterated | $26.78 | $27 | within 5% of price when set | +6.4% |
| 2026-01-27 | Cantor Fitzgerald | Neutral | maintained | $26.50 | $27 | within 5% of price when set | +5.6% |
| 2025-12-17 | Morgan Stanley | Equal-Weight | maintained | $25.04 | $27 | reached 2026-02-06 | -0.2% |
| 2025-12-15 | Bank of America | Neutral | maintained | $26.43 | $28 | reached 2026-03-31 | +5.5% |
| 2025-12-12 | Morgan Stanley | Equal-Weight | maintained | $25.85 | $28 | replaced 2025-12-17, new $27 | -0.1% |
| 2025-11-24 | Guggenheim | Buy | maintained | $25.22 | $35 | replaced 2026-03-24, new $36 | — |
Also in Pharma
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.